Adrenal Infarction - An Early and Late Complication of COVID-19: A Case Report

Mariam Gigiabdze; Keti Kebadze; Mariam Beriashvili; Mariam Dvaladze; Elene Vardosanidze; Ana Abuladze; Tamar Gigolashvili; Melita Modebadze

doi:10.47134/phms.v2i2.310

Authors

Mariam Gigiabdze Faculty of Medicine Tbilisi State Medical University
Keti Kebadze Faculty of Medicine Tbilisi State Medical University
Mariam Beriashvili Faculty of Medicine Tbilisi State Medical University
Mariam Dvaladze Faculty of Medicine Tbilisi State Medical University
Elene Vardosanidze Faculty of Public Health, Tbilisi State Medical University
Ana Abuladze Faculty of Public Health, Tbilisi State Medical University
Tamar Gigolashvili Faculty of Public Health, Tbilisi State Medical University
Melita Modebadze Faculty of Medicine, Caucasus International University

DOI:

https://doi.org/10.47134/phms.v2i2.310

Keywords:

COVID-19; Adrenal Infarct; Complications of COVID-19; Adrenal Insufficiency

Abstract

Progressive respiratory failure and the hyperinflammatory response are among the primary causes of death in COVID-19. Although various organ system complications have been identified post-COVID, among which one of the most important endocrine disorders is hypothalamus-pituitary-adrenal gland connection disruption, there is still little information about virus-induced adrenal gland tropism. Among the multisystemic effects of the COVID-19 pandemic, researchers are focusing on adrenal hemorrhages and infarcts. The aim of the article is to present and discuss clinical case of autoimmune adrenal gland failure developed post-COVID. The impact of COVID-19 was studied in 3 phases: The phase of acute active infection, Immediate post-infection phase and Long-term recovery phase. Adrenal insufficiency associated with COVID-19 has been reported in the literature in the context of hemorrhage and infarction. As a result of the studies, it was determined that the administration of large amounts of hydrocortisone to patients during the acute active phase of COVID-19 makes it impossible to fully evaluate the function of the gland. After stopping treatment with hydrocortisone, adrenal insufficiency was detected 1 month following the infarction. It has been established that during the long-term recovery phase, the possibility of insufficient cortisol is observed in most patients. In this case, the cause is central adrenal insufficiency. Considering all this, we can say that adrenal gland failure is a late phase complication of COVID-19. After transmission of COVID-19, complications are associated with insufficient production of cortisol by the adrenal gland. It is important to evaluate issues in post-COVID patients to avoid life-threatening adrenal crises.

References

Akbas EM, Akbas N. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Mar;165(1):1-7. doi: 10.5507/bp.2021.011. Epub 2021 Feb 4. PMID: 33542545. DOI: https://doi.org/10.5507/bp.2021.011

Alzahrani AS, Mukhtar N, Aljomaiah A, Aljamei H, Bakhsh A, Alsudani N, Elsayed T, Alrashidi N, Fadel R, Alqahtani E, Raef H, Butt MI, Sulaiman O. The Impact of COVID-19 Viral Infection on the Hypothalamic-Pituitary-Adrenal Axis. Endocr Pract. 2021 Feb;27(2):83-89. doi: 10.1016/j.eprac.2020.10.014. Epub 2020 Dec 15. PMID: 33554871; PMCID: PMC7837186.

Freire Santana M, Borba MGS, Baía-da-Silva DC, Val F, Alexandre MAA, Brito-Sousa JD, Melo GC, Queiroga MVO, Leão Farias ME, Camilo CC, Naveca FG, Xavier MS, Monteiro WM, Augusto Pivoto João G, Hajjar LA, Ordi J, Lacerda MVG, Ferreira LCL. Case Report: Adrenal Pathology Findings in Severe COVID-19: An Autopsy Study. Am J Trop Med Hyg. 2020 Oct;103(4):1604-1607. doi: 10.4269/ajtmh.20-0787. PMID: 32876012; PMCID: PMC7543860. DOI: https://doi.org/10.4269/ajtmh.20-0787

Kanczkowski W, Evert K, Stadtmüller M, Haberecker M, Laks L, Chen LS, Frontzek K, Pablik J, Hantel C, Beuschlein F, Kurth T, Gruber S, Aguzzi A, Varga Z, Bornstein SR. COVID-19 targets human adrenal glands. Lancet Diabetes Endocrinol. 2022 Jan;10(1):13-16. doi: 10.1016/S2213-8587(21)00291-6. Epub 2021 Nov 18. PMID: 34801110; PMCID: PMC8601687. DOI: https://doi.org/10.1016/S2213-8587(21)00291-6

Leyendecker P, Ritter S, Riou M, Wackenthaler A, Meziani F, Roy C, Ohana M. Acute adrenal infarction as an incidental CT finding and a potential prognosis factor in severe SARS-CoV-2 infection: a retrospective cohort analysis on 219 patients. Eur Radiol. 2021 Feb;31(2):895-900. doi: 10.1007/s00330-020-07226-5. Epub 2020 Aug 27. PMID: 32852586; PMCID: PMC7450155. DOI: https://doi.org/10.1007/s00330-020-07226-5

Popescu M, Terzea DC, Carsote M, Ghenea AE, Costache A, Popescu IAS, Biciuşcă V, Busuioc CJ, Ghemigian AM. COVID-19 infection: from stress-related cortisol levels to adrenal glands infarction. Rom J Morphol Embryol. 2022 Jan-Mar;63(1):39-48. doi: 10.47162/RJME.63.1.03. PMID: 36074666; PMCID: PMC9593124. DOI: https://doi.org/10.47162/RJME.63.1.03

Alzahrani, A. S. (2021). The Impact of COVID-19 Viral Infection on the Hypothalamic-Pituitary-Adrenal Axis. Endocrine Practice, 27(2), 83–89. https://doi.org/10.1016/j.eprac.2020.10.014 DOI: https://doi.org/10.1016/j.eprac.2020.10.014

Boughton, C. K. (2022). Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. The Lancet Healthy Longevity, 3(3). https://doi.org/10.1016/S2666-7568(22)00005-8 DOI: https://doi.org/10.1016/S2666-7568(22)00005-8

Clarke, S. A. (2022). Impact of COVID-19 on the Endocrine System: A Mini-review. Endocrinology (United States), 163(1). https://doi.org/10.1210/endocr/bqab203 DOI: https://doi.org/10.1210/endocr/bqab203

Frara, S. (2021). COVID-19 and the pituitary. Pituitary, 24(3), 465–481. https://doi.org/10.1007/s11102-021-01148-1 DOI: https://doi.org/10.1007/s11102-021-01148-1

Gupta, S. (2021). Association between Early Treatment with Tocilizumab and Mortality among Critically Ill Patients with COVID-19. JAMA Internal Medicine, 181(1), 41–51. https://doi.org/10.1001/jamainternmed.2020.6252 DOI: https://doi.org/10.1001/jamainternmed.2020.6252

Hermine, O. (2021). Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine, 181(1), 32–40. https://doi.org/10.1001/jamainternmed.2020.6820 DOI: https://doi.org/10.1001/jamainternmed.2021.2209

Jensterle, M. (2022). The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel. International Journal of Molecular Sciences, 23(13). https://doi.org/10.3390/ijms23137326 DOI: https://doi.org/10.3390/ijms23137326

Kanczkowski, W. (2022). Is there a role for the adrenal glands in long COVID? Nature Reviews Endocrinology, 18(8), 451–452. https://doi.org/10.1038/s41574-022-00700-8 DOI: https://doi.org/10.1038/s41574-022-00700-8

Luke, J. J. (2022). Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. The Lancet, 399(10336), 1718–1729. https://doi.org/10.1016/S0140-6736(22)00562-1 DOI: https://doi.org/10.1016/S0140-6736(22)00562-1

Mao, Y. (2021). The Adrenal Cortex, an Underestimated Site of SARS-CoV-2 Infection. Frontiers in Endocrinology, 11. https://doi.org/10.3389/fendo.2020.593179 DOI: https://doi.org/10.3389/fendo.2020.593179

Mirza, S. A. (2022). COVID-19 and the Endocrine System: A Review of the Current Information and Misinformation. Infectious Disease Reports, 14(2), 184–197. https://doi.org/10.3390/idr14020023 DOI: https://doi.org/10.3390/idr14020023

Morita, S. (2022). Isolated ACTH deficiency following immunization with the BNT162b2 SARS-CoV-2 vaccine: a case report. BMC Endocrine Disorders, 22(1). https://doi.org/10.1186/s12902-022-01095-3 DOI: https://doi.org/10.1186/s12902-022-01095-3

Puig-Domingo, M. (2021). COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. Endocrine, 72(2), 301–316. https://doi.org/10.1007/s12020-021-02734-w DOI: https://doi.org/10.1007/s12020-021-02734-w

Rodríguez, Y. (2022). Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. Journal of Autoimmunity, 132. https://doi.org/10.1016/j.jaut.2022.102898 DOI: https://doi.org/10.1016/j.jaut.2022.102898

Urhan, E. (2022). Investigation of pituitary functions after acute coronavirus disease 2019. Endocrine Journal, 69(6), 649–658. https://doi.org/10.1507/endocrj.EJ21-0531 DOI: https://doi.org/10.1507/endocrj.EJ21-0531